IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)

Basit Öğe Kaydı
dc.contributor.authorOdabas, Hatice
dc.contributor.authorUlas, Arife
dc.contributor.authorAydin, Kubra
dc.contributor.authorInanc, Mevlude
dc.contributor.authorAksoy, Asude
dc.contributor.authorYazilitas, Dogan
dc.contributor.authorTurkeli, Mehmet
dc.date.accessioned2024-04-24T17:49:56Z
dc.date.available2024-04-24T17:49:56Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS876en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.startpageS876en_US
dc.identifier.urihttps://hdl.handle.net/11468/23107
dc.identifier.volume8en_US
dc.identifier.wosWOS:000339624904137
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPrognostic Factorsen_US
dc.subjectSurvivalen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectSecond Line Treatmenten_US
dc.titleIS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)en_US
dc.titleIS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu